Checkpoint Therapeutics Inc (CKPT)
3.485
-0.02
(-0.71%)
USD |
NASDAQ |
Nov 04, 16:00
3.50
+0.02
(+0.43%)
After-Hours: 20:00
Checkpoint Therapeutics Research and Development Expense (TTM): 26.77M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 26.77M |
| March 31, 2024 | 36.24M |
| December 31, 2023 | 43.57M |
| September 30, 2023 | 49.50M |
| June 30, 2023 | 52.87M |
| March 31, 2023 | 50.98M |
| December 31, 2022 | 49.82M |
| September 30, 2022 | 63.25M |
| June 30, 2022 | 63.76M |
| March 31, 2022 | 58.91M |
| December 31, 2021 | 48.45M |
| September 30, 2021 | 28.94M |
| June 30, 2021 | 22.10M |
| March 31, 2021 | 17.93M |
| December 31, 2020 | 16.35M |
| September 30, 2020 | 14.94M |
| June 30, 2020 | 16.29M |
| Date | Value |
|---|---|
| March 31, 2020 | 17.38M |
| December 31, 2019 | 19.32M |
| September 30, 2019 | 26.02M |
| June 30, 2019 | 29.97M |
| March 31, 2019 | 31.30M |
| December 31, 2018 | 33.65M |
| September 30, 2018 | 25.15M |
| June 30, 2018 | 22.26M |
| March 31, 2018 | 22.31M |
| December 31, 2017 | 19.08M |
| September 30, 2017 | 21.91M |
| June 30, 2017 | 21.67M |
| March 31, 2017 | 21.61M |
| December 31, 2016 | 20.27M |
| September 30, 2016 | 17.88M |
| June 30, 2016 | 16.66M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
14.94M
Minimum
Sep 2020
63.76M
Maximum
Jun 2022
36.70M
Average
36.24M
Median
Mar 2024
Research and Development Expense (TTM) Benchmarks
| Fortress Biotech Inc | 71.93M |
| Avenue Therapeutics Inc | 5.642M |
| Journey Medical Corp | 12.53M |
| NovaBay Pharmaceuticals Inc | 0.043M |
| Palatin Technologies Inc | 22.40M |